Adverum soars on early gene therapy data; BerGenBio raises €45.4M on the heels of Covid-19 move
→ Another cut of positive interim data have lifted expectations that Adverum’s gene therapy that could give the anti-VEGF developers …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
